Stockreport

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications [...

Halozyme Therapeutics, Inc.  (HALO) 
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: halozyme.com/investors/default.aspx
PDF Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to IV Opdivo in the Phase 3 CheckMate-67T trial SAN DIEGO Dec. 30, 2024 /PRNews [Read more]